Announced that its South Korean licensing partner Kolon Life Science

Tissue Gene Announces Regulatory Allowance order Phase IIa trial with TG – C in South Korea take for osteoarthritis of the kneeTissue Gene, announced that its South Korean licensing partner Kolon Life Science, has regulatory allowance from the received Korea Food and Drug Administration to initiate a Phase IIa study in tissue genes – C in patients with severe osteoarthritis of the knee. TG-C was used for the localized delivery of allogeneic human cells expressing TGF – beta1, developed by inducing the regeneration of cartilage.

About Kolon Life Science,Kolon Life Science, a subsidiary of the colon , is a leading company in Korea for biochemical research and discovery in life sciences focus. In 2006, colon KLS founded by merging Tissue genes Asia Co. Ltd. With their existing pharmaceutical ingredients and specialty chemicals. For further information, please visit.

So that VEGF only approved the matrix of by invading cells, ‘explained Garc a? ‘That was very important because when you something hard, such as a matrix are can not be They. Non any vasculature growth in this area ‘. A multiannual program for John Moloney announcing Multi – Annual capital city the program on mental health, Irish.